Agilent Technologies Inc. (NYSE: A) today announced cancer research innovations in cell analysis and genomics that will be on show at the American Association for Cancer Research Annual Meeting, being held April 8 - 13, 2022 in New Orleans, Louisiana. “Cancer research is an important focus area for Agilent. The AACR conference presents an [...]
- Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, to present findings that provide a deeper understanding that tumor expression of genes related to extent of drug exposure, stratified by p53 status, is associated with clinical outcomes on the common chemotherapeutic regimens used [...]
Blueprint Medicines on Friday announced a clinical trial collaboration with AstraZeneca to study its EGFR inhibitors BLU-945 and BLU-701 in combination with AstraZeneca's Tagrisso (osimertinib) in non-small cell lung cancer. Blueprint will begin a trial cohort in its ongoing Phase I/II SYMPHONY trial to assess BLU-945 in combination with Tagrisso in patients with second-line [...]
With the help of single-cell RNA sequencing, a University of California, San Francisco-led team teased out some of the processes and regulatory pathways behind systemic lupus erythematosus (SLE), profiling shifts in blood cell composition and the expression of distinct blood cell types in more than 150 individuals with the heterogeneous autoimmune condition. "Single-cell sequencing [...]
Researchers at Stanford University have developed a new method of detecting cancer from circulating tumor DNA (ctDNA) that combines DNA fragmentation analysis with deep sequencing to infer RNA expression profiles of tumor cells. The ability to predict RNA expression from ctDNA is a first for blood-based cancer detection, and has potential for diagnosis, prognosis, [...]
Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved Yescarta® (axicabtagene ciloleucel) CAR T-cell therapy for adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Yescarta demonstrated a clinically meaningful and statistically significant improvement [...]
BabySeq, the next-generation sequencing-based universal screening program for newborns, is gearing up for a second, expanded study. The lead researchers said they want the four-year, $5.1 million grant to help address a lack of diversity in the first cohort. The original BabySeq cohort was not diverse and thus the findings are not generalizable, according [...]
SomaLogic said this week that it expects to launch more than 10 new products over the course of the coming year, including diagnostic assays and distributed research kits. On a conference call with investors following the release of the firm's fourth quarter and full-year 2021 financial results, company officials previewed 2022 for the Boulder, [...]
With two new instrument launches planned in the US this year, Roche is continuing to broaden its molecular diagnostic offerings. One key move Roche is making this year is a foray into the digital PCR market with its Digital LightCycler. Still "a very new technology" to laboratories, digital PCR allows for absolute nucleic acid [...]
NEW YORK – The US Food and Drug Administration on Wednesday approved Novartis' targeted radioligand therapy Pluvicto (177Lu-PSMA-617 or lutetium Lu 177 vipivotide tetraxetan) for progressive, metastatic castration-resistant prostate cancer (mCRPC) patients whose tumors express the prostate-specific membrane antigen (PSMA). The agency also approved Novartis' gallium-68-labeled imaging product Locametz (gallium Ga 68 gozetotide) as [...]
